vs
安捷伦科技（A）与Arcellx, Inc.（ACLX）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是Arcellx, Inc.的1087.1倍（$1.8B vs $1.7M）。安捷伦科技净利率更高（17.0% vs -3513.4%，领先3530.4%）。安捷伦科技同比增速更快（7.0% vs -89.2%）。安捷伦科技自由现金流更多（$175.0M vs $-58.9M）。过去两年安捷伦科技的营收复合增速更高（6.9% vs -79.5%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
A vs ACLX — 直观对比
营收规模更大
A
是对方的1087.1倍
$1.7M
营收增速更快
A
高出96.1%
-89.2%
净利率更高
A
高出3530.4%
-3513.4%
自由现金流更多
A
多$233.9M
$-58.9M
两年增速更快
A
近两年复合增速
-79.5%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $1.7M |
| 净利润 | $305.0M | $-58.1M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | -3850.2% |
| 净利率 | 17.0% | -3513.4% |
| 营收同比 | 7.0% | -89.2% |
| 净利润同比 | -4.1% | -23.4% |
| 每股收益（稀释后） | $1.07 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AACLX
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $1.7M | ||
| Q3 25 | $1.7B | $4.9M | ||
| Q2 25 | $1.7B | $7.6M | ||
| Q1 25 | $1.7B | $8.1M | ||
| Q4 24 | $1.7B | $15.3M | ||
| Q3 24 | $1.6B | $26.0M | ||
| Q2 24 | $1.6B | $27.4M |
净利润AACLX
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-58.1M | ||
| Q3 25 | $336.0M | $-55.8M | ||
| Q2 25 | $215.0M | $-52.8M | ||
| Q1 25 | $318.0M | $-62.3M | ||
| Q4 24 | $351.0M | $-47.1M | ||
| Q3 24 | $282.0M | $-25.9M | ||
| Q2 24 | $308.0M | $-27.2M |
毛利率AACLX
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率AACLX
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | -3850.2% | ||
| Q3 25 | 20.7% | -1248.3% | ||
| Q2 25 | 18.0% | -777.4% | ||
| Q1 25 | 22.4% | -847.6% | ||
| Q4 24 | 24.0% | -348.2% | ||
| Q3 24 | 21.1% | -129.1% | ||
| Q2 24 | 23.1% | -127.8% |
净利率AACLX
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -3513.4% | ||
| Q3 25 | 19.3% | -1127.1% | ||
| Q2 25 | 12.9% | -698.6% | ||
| Q1 25 | 18.9% | -766.0% | ||
| Q4 24 | 20.6% | -308.4% | ||
| Q3 24 | 17.9% | -99.4% | ||
| Q2 24 | 19.6% | -99.3% |
每股收益（稀释后）AACLX
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-1.01 | ||
| Q3 25 | $1.18 | $-0.99 | ||
| Q2 25 | $0.75 | $-0.94 | ||
| Q1 25 | $1.11 | $-1.13 | ||
| Q4 24 | $1.23 | $-0.87 | ||
| Q3 24 | $0.97 | $-0.48 | ||
| Q2 24 | $1.05 | $-0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $450.3M |
| 总债务越低越好 | $3.0B | — |
| 股东权益账面价值 | $6.9B | $402.4M |
| 总资产 | $12.8B | $604.0M |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资AACLX
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $450.3M | ||
| Q3 25 | $1.5B | $461.4M | ||
| Q2 25 | $1.5B | $453.1M | ||
| Q1 25 | $1.5B | $543.3M | ||
| Q4 24 | $1.3B | $587.4M | ||
| Q3 24 | $1.8B | $574.3M | ||
| Q2 24 | $1.7B | $516.7M |
总债务AACLX
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
股东权益AACLX
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $402.4M | ||
| Q3 25 | $6.4B | $440.8M | ||
| Q2 25 | $6.1B | $392.2M | ||
| Q1 25 | $6.0B | $416.9M | ||
| Q4 24 | $5.9B | $454.8M | ||
| Q3 24 | $5.9B | $483.0M | ||
| Q2 24 | $6.2B | $487.2M |
总资产AACLX
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $604.0M | ||
| Q3 25 | $12.2B | $655.9M | ||
| Q2 25 | $12.2B | $619.1M | ||
| Q1 25 | $11.9B | $648.1M | ||
| Q4 24 | $11.8B | $711.3M | ||
| Q3 24 | $11.0B | $764.9M | ||
| Q2 24 | $10.9B | $734.3M |
负债/权益比AACLX
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $-58.2M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $-58.9M |
| 自由现金流率自由现金流/营收 | 9.7% | -3563.4% |
| 资本支出强度资本支出/营收 | 5.2% | 46.2% |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | $-212.6M |
8季度趋势，按日历期对齐
经营现金流AACLX
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $-58.2M | ||
| Q3 25 | $362.0M | $-49.2M | ||
| Q2 25 | $221.0M | $-39.7M | ||
| Q1 25 | $431.0M | $-63.1M | ||
| Q4 24 | $481.0M | $-46.0M | ||
| Q3 24 | $452.0M | $30.7M | ||
| Q2 24 | $333.0M | $-36.2M |
自由现金流AACLX
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $-58.9M | ||
| Q3 25 | $259.0M | $-49.5M | ||
| Q2 25 | $107.0M | $-40.2M | ||
| Q1 25 | $334.0M | $-63.9M | ||
| Q4 24 | $388.0M | $-47.5M | ||
| Q3 24 | $360.0M | $28.4M | ||
| Q2 24 | $230.0M | $-39.5M |
自由现金流率AACLX
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | -3563.4% | ||
| Q3 25 | 14.9% | -1000.3% | ||
| Q2 25 | 6.4% | -532.4% | ||
| Q1 25 | 19.9% | -786.4% | ||
| Q4 24 | 22.8% | -311.3% | ||
| Q3 24 | 22.8% | 109.2% | ||
| Q2 24 | 14.6% | -144.1% |
资本支出强度AACLX
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 46.2% | ||
| Q3 25 | 5.9% | 6.0% | ||
| Q2 25 | 6.8% | 6.4% | ||
| Q1 25 | 5.8% | 9.6% | ||
| Q4 24 | 5.5% | 9.8% | ||
| Q3 24 | 5.8% | 8.8% | ||
| Q2 24 | 6.5% | 11.7% |
现金转化率AACLX
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
ACLX
暂无分部数据
